ReviewJournal of autoimmunity2008
Extreme genetic risk for type 1A diabetes in the post-genome era.
Review in Journal of autoimmunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Primary hyperaldosteronism associated with type 3 autoimmune polyendocrine syndrome: A rare case report.Clinical case reports · 2024Article
- Assessment of immune-alternations and their correlations with therapeutic outcomes of transplantation of autologous Mesenchymal and Allogenic fetal stem cells in patients with type 1 diabetes: a study protocol.Journal of diabetes and metabolic disorders · 2021Article
- Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era.Journal of translational medicine · 2021Review
- A peripheral blood transcriptomic signature predicts autoantibody development in infants at risk of type 1 diabetes.JCI insight · 2018Article
- PTPN22 and islet-specific autoimmunity: What have the mouse models taught us?World journal of diabetes · 2017Review
- The MHC locus and genetic susceptibility to autoimmune and infectious diseases.Genome biology · 2017Review
- Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?Current diabetes reviews · 2017Review
- The next big idea.Diabetes technology & therapeutics · 2013Article
- Targeting the trimolecular complex: the pathway towards type 1 diabetes prevention.Diabetes technology & therapeutics · 2013Article
- Type 1 diabetes: primary antigen/peptide/register/trimolecular complex.Immunologic research · 2013Review
- Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving.Hepatology (Baltimore, Md.) · 2011Review
- Genetics of type 1 diabetes.Clinical chemistry · 2011Review
- Divergent motifs but overlapping binding repertoires of six HLA-DQ molecules frequently expressed in the worldwide human population.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Diagnostic challenges in celiac disease and the role of the tissue transglutaminase-neo-epitope.Clinical reviews in allergy & immunology · 2010Review
- A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes.Journal of autoimmunity · 2010Article
- Early over expression of messenger RNA for multiple genes, including insulin, in the Pancreatic Lymph Nodes of NOD mice is associated with Islet Autoimmunity.BMC medical genomics · 2009Article
- Analysis of T cell receptor beta chains that combine with dominant conserved TRAV5D-4*04 anti-insulin B:9-23 alpha chains.Journal of autoimmunity · 2009Article
- Technologies for diabetes genomics.Journal of diabetes science and technology · 2009Review
- Probiotics and immunity.Journal of gastroenterology · 2009Review
- Prevention of type 1A diabetes mellitus.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A series of genes and loci influencing the genetic risk of type 1A (immune-mediated) diabetes are now well characterized. These include genes of the major histocompatibility complex (MHC), polymorphisms 5' of the insulin gene, and PTPN22, as well as more recently defined loci from genome-wide association studies. By far the major determinants of risk for type 1A diabetes are genes within or linked to the MHC and in particular alleles of class II genes (HLA-DR, DQ, and DP). There is evidence that MHC class I alleles contribute and there are additional MHC-linked influences such that for a major subset of relatives of patients there is a risk as high as 80% for siblings, and for the general population a risk as high as 20% can be defined at birth just by analyzing the MHC. We believe the search for additional MHC loci will require analysis of the remarkable long-range identity (up to 9 million base pairs) of extended MHC haplotypes. Current prediction algorithms will likely be greatly improved for the general population when the additional contributing loci of the MHC are defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.